Feature

Medicare sets outpatient CAR T-cell therapy rates


 


Time will tell how reimbursement plays out during clinical practice, but one thing is for certain: The current CAR T-cell therapies are only the beginning, Dr. Maziarz said.

“Genetically-engineered cell products are going to explode over the next decade,” he said. “This is not the end of the line, this is the starting point.”

Dr. Maziarz has received consulting fees from Novartis, Juno Therapeutics, and Kite Pharma. Dr. Heslop has received consulting fees from Novartis, has conducted research for Cell Medica and holds intellectual property rights/patents from Cell Medica, and has ownership interest in ViraCyte and Marker Therapeutics. Dr. Gellad reports grants from Express Scripts.

Pages

Recommended Reading

VIDEO: Fix physician burnout? You need more than yoga
MDedge Hematology and Oncology
MDedge Daily News: Bridging medicine’s gender gap
MDedge Hematology and Oncology
MDedge Daily News: Physician burnout needs more than yoga
MDedge Hematology and Oncology
Speakers at FDA advisory meetings have hidden conflicts
MDedge Hematology and Oncology
MDedge Daily News: Which nonopioids are ripe for abuse?
MDedge Hematology and Oncology
MDedge Daily News: Lupus is quietly killing young women
MDedge Hematology and Oncology
What’s in a name? Get ready for the feds’ Promoting Interoperability program
MDedge Hematology and Oncology
MDedge Daily News: How smartphones could battle oral cancer
MDedge Hematology and Oncology
‘Rapid autopsy’ programs seek clues to cancer within hours of death
MDedge Hematology and Oncology
Female physicians face enduring wage gap
MDedge Hematology and Oncology